Ana Lucia de Almeida Kater

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
In addition to their expected effects on lipid profile, lipid-lowering agents may reduce cardiovascular events because of effects on nonclassic risk factors such as insulin resistance and inflammation. Ezetimibe specifically blocks the absorption of dietary and biliary cholesterol as well as plant sterols. Although it is known that an additional reduction(More)
  • 1